Abstract. A number of previous studies have reported that sex steroid hormones, including estrogens, are involved in the regulation of the thymic function. The aim of the present study was to investigate the expression of estrogen receptor β5 (ERβ5) in thymic tumors and the correlation between ERβ5 expression and thymoma biological characteristics. The expression levels of ERβ5 in thymic epithelial tumors was evaluated in 103 patents using immunohistochemical staining and reverse transcription-quantitative polymerase chain reaction. In addition, an indirect immunofluorescence assay was performed to evaluate the ERβ5 expression levels in the TC1889 and T1682 cell lines. The survival outcome was estimated using Kaplan-Meier plots. The results indicated that ERβ5 expression was mainly located in the thymic tumor cell cytoplasm (87.37%; 90/103 cases) and overexpression was observed in thymic tumors compared with normal thymic tissues (P=0.001). Using the Kruskal-Wallis test, a statistically significant association was observed between cytoplasmic ERβ5 (cERβ5) expression and thymic tumor subtypes (P=0.024) and stages (P=0.003 and R=-0.376). The Kaplan-Meier plots revealed that cERβ5 expression was significantly associated with improved overall and progression-free survival (P=0.008 and P=0.004, respectively). The present study suggested that overexpression of cERβ5 may indicate an improved prognosis and may be involved in the underlying mechanism through which estrogen inhibits thymoma and thymic carcinoma development.
Introduction
The ability of sex hormones to affect lymphocyte development is well-known (1-3), and particularly the ability of estrogen to inhibit postnatal thymocyte development (3) (4) (5) (6) . Extended exposure to sex steroid hormones, for instance during estrogen therapy and pregnancy, results in thymic atrophy and loss of cellularity in humans and animals (3) . The estrogen-triggered thymic atrophy may result in sexual dimorphism in the immune response and downregulation of autoimmune responses (7) (8) (9) . A number of studies have reached the conclusion that estrogen induces thymic atrophy, and certain studies have demonstrated that estrogen may affect the development of thymomas and thymic carcinomas (9) (10) (11) . However, verification of such findings is not possible due to limited data, and the expression and distribution of estrogen receptors in thymomas and thymic carcinomas remain controversial (10) (11) (12) . In addition, the biological effect of estrogen is unclear. Estrogen has been demonstrated to exhibit pleiotropic effects by binding to intracellular receptors, including estrogen receptors (ER)α and β. Previous meta-analyses observed that ERα was not overexpressed in thymic tumors (including thymomas and thymic carcinomas) compared with in benign thymic tissues, whereas ERβ was overexpressed, which may indicate binding to ERβ and complex estrogen physiological effects (12, 13) .
ERβ has at least five variant isoforms (ERβ1-5), which have been described in numerous human organs or tissues, including breast and prostate cancer (13) (14) (15) . Notably, no evident structural differences exist among these variants, for example they all lack certain key parts, such as helix 12, however, regarding their function and distribution, certain differences have been identified; ERβ2 is mainly located in the nucleus whereas ERβ5 is mainly found in the cytoplasm in cancer tissues (13, 14) .
Therefore, the present study aimed to investigate the expression and distribution of ERβ5 in thymomas and thymic carcinomas, and further analyze the correlation between ERβ5 expression and prognostic factors. The thymic carcinoma cell line, TC1889, and the thymoma cell line, T1682, were established, characterized and verified as previously described (18) .
Patients and methods

Patient
Immune microarray and evaluation of immunoreactivity.
Tissue microarrays (TMAs) were constructed from the paraffin-embedded blocks of the 129 thymic specimens, using a tissue array device (cat. no. BNSW-001_TY9184; Shanghai Outdo Biotech Co., Ltd., Shanghai, China). Representative tumor areas were marked in each paraffin-embedded specimen and at least two areas were sampled. The diameter of the tissue cylinders was 0.6 mm, made using tissue chip drilling apparatus (Shanghai Outdo Biotech Co., Ltd.). For ERβ5 staining, the monoclonal ERβ5 antibody (clone 5/25) was used at a dilution of 1:50, which was demonstrated to be highly specific in immunohistochemical assays performed in this study. Antigen retrieval was performed in 0.01 mol/l sodium citrate buffer (pH 6.0) in the microwave for 15 min. To establish the negative controls, the same procedure was followed, without the primary antibody. A previously described scoring system was adopted (19) , the tissue microarrays were digitized and cytoplasmic ERβ5 (cERβ5) or nuclear ERβ5 (nERβ5) immunoreactivity was scored between -and +++ (-, no staining; +, weak staining; ++, moderate staining; +++, strong staining). The percentage of tumor cells displaying staining for cERβ5 or nERβ5 was determined and calculated as the average of six high power fields per specimen. The cases were scored independently by three specialists and discordant results were re-evaluated to reach consensus.
Indirect immunofluorescence assay (IIFA).
TC1889 and T1682 cells were cultured in RPMI-media containing HEPES supplemented with 10% fetal calf serum and 1% penicillin/streptomycin (Sigma-Aldrich) in an atmosphere containing 5% CO 2 at 37˚C. For IIFA, the anti-ERβ5 antibody (clone 5/25) was incubated at a dilution of 1:500 at 4˚C overnight. Fluorescein isothiocyanate-conjugated goat anti-human immunoglobulin G (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was used as the secondary antibody and incubated at a dilution of 1:100 for 1 h at room temperature. Cells were washed with phosphate-buffered saline (J-H Biotechnology Ltd., Shanghai, China) and mounted using 10 mg/ml DAPI (Sigma-Aldrich) in aqueous mountant (Dako North America, Inc., Carpinteria, CA, USA). A fluorescence microscope (Leica DM1000; Leica Microsystems GmbH, Wetzlar, Germany) was used for examination of the samples.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA was extracted using the RNeasy mini kit (Qiagen, Crawley, UK) with additional purification by centrifugation at 12,000 x g for 15 min through QIAshredder spin columns (Qiagen). The total RNA concentration and purity were calculated using the Nanodrop system (Labtech International Ltd., Lewes, UK). Subsequently, cDNA synthesis was performed using the SYBR ® ExScript RT-PCR kit (Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer's instructions. Quantitative PCR was performed using the SYBR ® Premix Ex Taq™ II kit (Takara Biotechnology Co., Ltd.) with a LightCycler system (Roche Diagnostics, Basel, Switzerland). The primers used were as follows: ERβ5 forward, 5'-CGGAAGCTGGCTCACTTGCT-3', and reverse, 5'-CTTCACCCTCCGTGGAGCAC-3'; and β-actin forward, 5'-GTGGGGCGCCCAGGCACCAC-3', and reverse, 5'-CTCCTTAATGTCACGCACGATTT-3'. The reaction volume was 50 µl and comprised the following final Table I . Expression of nuclear and cytoplasmic ERβ5 in thymic tumor and normal tissues. 
Results
Expression of ERβ5 in thymic tumors and normal thymic tissues.
The results of the ERβ5 immunohistochemical assay for the 129 cases are listed in Tables I-III . The majority of thymic tumors exhibited ERβ5-positive staining (99.02%; Table II . Correlation between cytoplasmic and nuclear ERβ5 expression and patient characteristics. Table III . Correlation between cytoplasmic ERβ5 expression and tumor pathological characteristics. 102/103 cases), with only one case presenting negative staining. In addition, 87.37% (90/103) of the cases were positive for cERβ5, 11.62% of the cases were positive for nERβ5 and 15 cases were positive for nERβ5 and cERβ5 (Table I ; Fig. 1 A1-A6 ). In particular, the thymic carcinomas exhibited strong positive staining, while only 38.46% of normal thymic tissues (10/26; Table I ) exhibited positive staining. Furthermore, overexpression of cERβ5 was observed in the thymic tumors compared with normal thymic tissues, and this difference was statistically significant (P=0.001); by contrast, nERβ5 was not overexpressed in thymic tumors (P=0.112; Table I ). Similar results were observed in the T1682 and TC1889 cell lines following IIFA (Fig. 1B) . mRNA quantification was conducted during RT-qPCR, and the results were compared against β-actin, which was used as the internal reference gene. The ERβ5 expression levels ranged between 0.468 and 13.292 (median, 5.672; data not shown). In advanced clinical stages, the mean level of ERβ5 gene expression was lower (Fig. 1C) .
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Association between cERβ5 or nERβ5 expression levels and patient characteristics. The association between ERβ5 expression and a range of standard patient characteristics were investigated and are listed in Table II . No positive correlation was detected between cERβ5 expression and patient characteristics, including gender, age and tumor sizes (P=0.245, P=0.514 and P=0.614, respectively). Notably, although no statistically significant association was observed between tumor sizes and cERβ5 expression, the latter was demonstrated to be important in the progression of thymic tumors (Table II) .
In addition, no statistically significant association was determined between nERβ5 expression and patient characteristics.
Association of ERβ5 staining with histological subtype and stage. Since cERβ5 was overexpressed in the thymic tumors, a statistically significant correlation was observed between cERβ5 expression and thymoma subtypes (P=0.024; Table III) , which presented a particularly strong positive expression in thymic carcinomas. In addition, a statistically significant difference was identified between cERβ5 staining and thymic tumor stages (P=0.003); however, a negative correlation was observed (Table III ; R=-0.376).
By contrast, no statistically significant differences were observed between nERβ5 staining and thymomas subtypes or stages (P=0.653; data not shown).
Kaplan-Meier plot results of TMA analysis.
The TMA analysis revealed that cERβ5 staining was significantly associated with improved OS, whereas nERβ5 immunoreactivity was not associated with OS (data not shown). In addition, cERβ5 staining was correlated with improved PFS, which implied that cERβ5 had a negative biological effect in the development of thymic tumors (Fig. 2) .
Discussion
Exposure to sex steroid hormones, for instance during estrogen therapy, results in thymic atrophy and loss of cellularity in animals (18, 20, 21) . Thymic atrophy induced by estrogens contributes towards certain complicated and unclear mechanisms. A large number of studies have reported that estrogen is involved in biological functions in human and animal organs through estrogen receptors, including ERα and ERβ (which has at least five isoforms, such as ERβ5) (22) (23) (24) . At present, controversial findings exist on the expression of estrogen receptors in thymic tumors, since a number studies reported overexpression of ERβ in these tumors, whereas others studies obtained contradictory results (11, 12, 13, 19) .
In the present study, the expression of ERβ5 was investigated by immunohistochemistry. Overexpression of ERβ was identified and strong evidence was provided on the controversial function of estrogen receptors in thymic tumors; however, the expression of ERα was not investigated in the present study.
To the best of our knowledge, the present study is the first to compare the protein expression levels of ERβ5 in specimens from a cohort of patients with thymic tumors (n=103). The immunohistochemical expression of ERβ5 was analyzed in a set of TMAs using an ERβ5 specific antibody. The results revealed that ERβ5 was overexpressed and predominantly located in the cytoplasm of thymic tumors, which indicated the important role of this receptor in the progression of thymic tumors. Furthermore, the present study identified statistically significant differences between cERβ5 expression and thymic tumor subtypes and stages. Notably, a negative correlation was identified between a high expression of cERβ5 and tumor stages (R=-0.376), indicating that cERβ5 may inhibit thymic tumor progression, providing an insight into the estrogen biological mechanism.
As previously reported (25) (26) (27) , the classic hormonal mechanism involves the binding of estrogens to ERs in the nucleus, thus promoting the association with specific estrogen response elements in the promoters of target genes. At the same time, ERs regulate the expression of numerous genes without directly binding to DNA, but through protein-protein interactions with certain factors, such as phosphoinositide 3-kinase. According to the results of the present study, ERβ5 was mainly localized in the cytoplasm, which may indicate that estrogen activated cERβ5 by protein-protein interaction signaling and then inhibited thymic tumor development.
Further analysis using Kaplan-Meier plots revealed that a high expression of cERβ5 was a significant prognostic factor of thymic tumors. In addition, the present study indicated that high cERβ5 expression in thymic tumors was correlated with longer OS and PFS, which was in accordance with previous results (18, 20, 21, 23, 28, 29) . However, the fact that cERβ5 was overexpressed in thymic tumors, while having an inhibiting biological effect, suggested that cERβ5 may be involved in other functions of the thymic tumor development and progression. The results of the present study indicated that the underlying mechanism of estrogen may be complex in thymic tumor development and requires further investigation.
Due to difficulties in the identification of ERβ isoforms in human thymic tumors, as well as other factors, ERβ variants have not been previously reported in detail. To the best of our knowledge, in the present study, ERβ5 was identified in thymic tumor tissues for the first time; however, it was unclear whether other ERβ isoforms were also expressed, as reported in some cancer tissues, including breast and prostate cancer (28) (29) (30) . The results of the present study demonstrated that estrogen exerts a biological effect on thymic tumors through ERβ5, at least. Furthermore, the underlying mechanism may involve protein-protein interaction signaling in the thymic tumor cell cytoplasm, although this remains unclear.
In conclusion, the present study suggested that, in part, ERβ5-mediated functions may be a potential underlying mechanism through which estrogens alter susceptibility to thymic tumors. In order to develop more selective and specific ER modulators for the treatment of thymic tumor patients, further studies are required on ligand activation of ERβ5-mediated functions in thymic tumor patients.
